Literature DB >> 24037217

The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.

Jamie Koo1, Xiaoyan Zhou, Elizabeth Moschiano, Mariza De Peralta-Venturina, Richard B Mertens, Deepti Dhall.   

Abstract

Rectal neuroendocrine tumors (NETs) can be classified by histologic pattern and secretory products. Recently, rectal NETs have been noted to exhibit immunohistochemical (IHC) positivity for Islet 1 and PAX8, which are generally considered markers for NETs of pancreatic origin. In this study, we sought to characterize the IHC staining profile of rectal NETs and determine whether there was any correlation between the histologic pattern of rectal NETs and their IHC profile. Fifty-six primary rectal NETs were histologically reviewed and stained with antibodies against Islet 1, PAX8, CDX2, chromogranin A, and synaptophysin. In a subset of 31 cases, immunoreactivity for serotonin, pancreatic polypeptide (PP), and prostatic acid phosphatase (PAP) was also studied. By morphology, the tumors studied included 55 % trabecular, 27 % solid nested, 4 % acinar, and 14 % mixed patterns. Islet 1 was positive in 89 % and PAX8 in 79 % of cases. CDX2 was negative in all 56 cases. Cytoplasmic staining was observed for chromogranin A in 30 % of cases and for synaptophysin in all 56 cases. Cytoplasmic staining for serotonin, PP, and PAP was present in 16, 61, and 97 % of cases, respectively. There was no correlation between histologic pattern and IHC staining pattern with any of the antibodies studied. We have demonstrated that Islet 1 and PAX8 are not entirely specific for NETs of pancreatic origin, as they are expressed in a majority of rectal NETs. Since rectal NETs may show an IHC staining profile which mirrors that of pancreatic NETs (Islet 1 and PAX8-positive, CDX2-negative), a metastatic rectal NET should be considered in the differential diagnosis and ruled out clinically in the work-up of a metastatic NET of unknown primary origin which exhibits this staining profile.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24037217     DOI: 10.1007/s12022-013-9264-9

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  30 in total

Review 1.  Functions of LIM-homeobox genes.

Authors:  O Hobert; H Westphal
Journal:  Trends Genet       Date:  2000-02       Impact factor: 11.639

2.  Synaptic vesicle protein 2, A new neuroendocrine cell marker.

Authors:  G M Portela-Gomes; A Lukinius; L Grimelius
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases.

Authors:  J Soga; K Tazawa
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

4.  [Immunohistochemical study of 17 cases of rectal neuroendocrine tumors].

Authors:  J Chetritt; C Sagan; M F Heymann; M F Le Bodic
Journal:  Ann Pathol       Date:  1996       Impact factor: 0.407

5.  Prostate-specific acid phosphatase in carcinoid tumors.

Authors:  N Kimura; N Sasano
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

6.  Prostatic acid phosphatase in carcinoid tumors. Immunohistochemical and immunoblot studies.

Authors:  N Azumi; S T Traweek; H Battifora
Journal:  Am J Surg Pathol       Date:  1991-08       Impact factor: 6.394

7.  CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors.

Authors:  Stefano La Rosa; Elena Rigoli; Silvia Uccella; Anna Maria Chiaravalli; Carlo Capella
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

8.  Glucagon, glicentin, proglucagon, PYY, PP and proPP-icosapeptide immunoreactivities of rectal carcinoid tumors and related non-tumor cells.

Authors:  R Fiocca; G Rindi; C Capella; L Grimelius; J M Polak; T W Schwartz; N Yanaihara; E Solcia
Journal:  Regul Pept       Date:  1987-01

9.  ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin.

Authors:  Abbas Agaimy; Katharina Erlenbach-Wünsch; Björn Konukiewitz; Anja M Schmitt; Ralf J Rieker; Michael Vieth; Franklin Kiesewetter; Arndt Hartmann; Giuseppe Zamboni; Aurel Perren; Günter Klöppel
Journal:  Mod Pathol       Date:  2013-03-15       Impact factor: 7.842

10.  Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors.

Authors:  Amitabh Srivastava; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2009-04       Impact factor: 6.394

View more
  9 in total

Review 1.  Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

Authors:  Stefano La Rosa; Fausto Sessa; Silvia Uccella
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

Review 2.  Pathology of Neuroendocrine Tumours of the Female Genital Tract.

Authors:  Brooke E Howitt; Paul Kelly; W Glenn McCluggage
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

Review 3.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 4.  High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and back.

Authors:  Stefano La Rosa; Fausto Sessa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

Review 5.  Metastatic Neuroendocrine Neoplasms of Unknown Primary: Clues from Pathology Workup.

Authors:  Carl Christofer Juhlin; Jan Zedenius; Anders Höög
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

6.  Neuroendocrine Liver Metastasis-a Specific Set of Markers to Detect Primary Tumor Sites.

Authors:  Andreas Selberherr; Oskar Koperek; Philipp Riss; Christian Scheuba; Reto Kaderli; Aurel Perren; Bruno Niederle
Journal:  Endocr Pathol       Date:  2019-03       Impact factor: 3.943

7.  Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask.

Authors:  Manuela Albertelli; Federica Grillo; Fabio Lo Calzo; Giulia Puliani; Carmen Rainone; Annamaria Anita Livia Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

Review 8.  Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.

Authors:  Martine Bocchini; Fabio Nicolini; Stefano Severi; Alberto Bongiovanni; Toni Ibrahim; Giorgia Simonetti; Ilaria Grassi; Massimiliano Mazza
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244

9.  An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.

Authors:  Atsuko Kasajima; Björn Konukiewitz; Anna Melissa Schlitter; Wilko Weichert; Günter Klöppel
Journal:  Virchows Arch       Date:  2021-09-09       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.